ORIGINAL PAPER
GST gene family polymorphism and the risk of colorectal cancer
in patients with type 2 diabetes
1
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
2
Department of Pathomorphology, Central Clinical Hospital of MSWiA, Warsaw, Poland
3
Department of Internal Medicine, Tytus Chałubiński Hospital, Zakopane, Poland
4
Institute of Biology, Jan Kochanowski University, Kielce, Poland
Submission date: 2021-03-24
Final revision date: 2021-09-17
Acceptance date: 2021-09-19
Publication date: 2021-09-30
Medical Studies 2021;37(3):218-225
KEYWORDS
TOPICS
ABSTRACT
Aim:
To investigate whether the polymorphisms of GSTP1, GSTT1 and GSTM1 genes are associated with colorectal cancer in a sample of Polish patients with and without type 2 diabetes.
Material and methods:
Over 200 patients aged > 40 years were recruited and divided into 4 age-matched groups: patients with diagnosed type 2 diabetes, patients with diagnosed type 2 diabetes and colorectal cancer, patients with colorectal cancer and without type 2 diabetes and patients without type 2 diabetes and without colorectal cancer. DNA for genetic testing was isolated from blood samples. The GST gene polymorphism was examined using qPCR method, with TaqMan probes. It included GSTP1 SNP Ile105Val (rs1695) polymorphism, and deletion of copies of GSTT1 and GSTM1 genes (genotypes GSTT1 null/null and GSTM1 null/null).
Results:
The analysis of the frequency of GST gene polymorphisms in the group of patients with type 2 diabetes and colorectal cancer compared to patients with type 2 diabetes showed no statistically significant differences. There were also no statistically significant differences in the distribution of GST gene polymorphisms between patients with diabetes or/and colorectal cancer and population without these diseases.
Conclusions:
Extending the analysis to further genetic and environmental factors and taking into account their mutual interactions is needed to search for the relationship between type 2 diabetes and an increased risk of colorectal cancer.
To investigate whether the polymorphisms of GSTP1, GSTT1 and GSTM1 genes are associated with colorectal cancer in a sample of Polish patients with and without type 2 diabetes.
Material and methods:
Over 200 patients aged > 40 years were recruited and divided into 4 age-matched groups: patients with diagnosed type 2 diabetes, patients with diagnosed type 2 diabetes and colorectal cancer, patients with colorectal cancer and without type 2 diabetes and patients without type 2 diabetes and without colorectal cancer. DNA for genetic testing was isolated from blood samples. The GST gene polymorphism was examined using qPCR method, with TaqMan probes. It included GSTP1 SNP Ile105Val (rs1695) polymorphism, and deletion of copies of GSTT1 and GSTM1 genes (genotypes GSTT1 null/null and GSTM1 null/null).
Results:
The analysis of the frequency of GST gene polymorphisms in the group of patients with type 2 diabetes and colorectal cancer compared to patients with type 2 diabetes showed no statistically significant differences. There were also no statistically significant differences in the distribution of GST gene polymorphisms between patients with diabetes or/and colorectal cancer and population without these diseases.
Conclusions:
Extending the analysis to further genetic and environmental factors and taking into account their mutual interactions is needed to search for the relationship between type 2 diabetes and an increased risk of colorectal cancer.
REFERENCES (26)
1.
Gonzalez N, Prieto I, del Puerto-Nevado L, Portal-Nuñez S,Ardura JA, Corton M, Fernández-Fernández B, Aguilera O, Gomez-Guerrero C, Mas S, Moreno JA, Ruiz-Ortega M, Sanz AB, Sanchez-Niño MD, Rojo F, Vivanco F, Esbrit P, Ayuso C, Alvarez-Llamas G, Egido J,García-Foncillas J, Ortiz A, Diabetes Cancer Connect Consortium. 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. Oncotarget 2017; 8: 18456-18485.
2.
Khodaeian M, Enayati S, Tabatabaei-Malazy O, Amoli MM. Association between genetic variants and diabetes mellitus in Iranian populations: a systematic review of observational studies. J Diab Res 2015; 2015: 585917.
3.
Piechowska AM, Wawszczak M, Cedro A, Głuszek S. Suppressor genes as molecular markers of colorectal cancer – a review of the latest reports. Medical Studies 2020; 36: 35-45.
4.
Thier R, Brüning T, Roos PH, Rihs HP, Golka K, Ko Y, Bolt HM. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes. Int J Hyg Environ Health 2003; 206: 149-171.
5.
Hollman AL, Tchounwou PB, Huang HC. The Association between gene-environment interactions and diseases involving the human GST superfamily with SNP variants. Int J Environ Res Public Health 2016; 13: 379.
6.
Sun L, Zhang Y, Xiong Y. GSTM1 and GSTT1 null genotype and diabetic retinopathy: a metaanalysis. Int J Clin Exp Med 2015; 8: 1677-1683.
7.
Klusek J, Nasierowska-Guttmejer A, Kowalik A, Wawrzycka I, Lewitowicz P, Chrapek M, Głuszek S. GSTM1, GSTT1, and GSTP1 polymorphisms and colorectal cancer risk in Polish nonsmokers. Oncotarget 2018; 9: 21224-21230.
8.
Grubisa I, Otasecvic P, Despotovic N, Dedic V, Milašin J, Vucinic N. Genetic polymorphism of glutathione S-transferase P1 (GSTP1) Ile105Val and susceptibility to atherogenesis in patients with type 2 diabetes mellitus. Genetika 2013; 45: 227-236.
9.
Orlewski J, Orlewska E. Effects of genetic polymorphisms of glutathione S-transferase genes (GSTM1, GSTT1 and GSTP1) on the risk of diabetic nephropathy: a meta-analysis. Pol Arch Med Wew 2015; 125: 649-658.
10.
Raza ST, Abbas S, Ahmad A, Ahmed F, Zaidi ZH, Mahdi F. Association of glutathione S-transferase (GSTM1 and GSTT1) and FTO gene polymorphisms with type 2 diabetes mellitus cases in northern India. BJMG 2014; 17: 47-54.
11.
Rodrigues-Fleming GH, de Mendonca Fernandes GM, Russo A, Biselli-Chicote PM, Netinho JG, Pavarino EC, Goloni-Bertolo EM. Molecular evaluation of glutathione S transferase family genes in patients with sporadic colorectal cancer. World J Gastroenterol 2018; 24: 4462-4471.
12.
Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprevention and drug resistance part I. Crit Rev Biochem Mol Biol 1995; 30: 445-600.
13.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 Suppl 1: S62-S69.
14.
Venugopal A, Stoffel EM. Colorectal cancer in young adults. Curr Treat Options Gastroenterol 2019; 17: 89-98.
15.
Selph S, Dana T, Blazina I, Bougatsos C, Patel H, Chou R. Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2015; 162: 765-776.
16.
Banerjee M, Vats P. Reactive metabolites and antioxidant gene polymorphisms in type 2 diabetes mellitus. Indian J Hum Genet 2014; 20: 10-19.
17.
Gusti AMT, Qusti SY, Bahijri SM, Toraih EA, Bokhari S, Attallah SM, Alzahrani A, Aslhehri WMA, Alotaibi H, Fawzy MS. Glutathione S-transferase (GSTT1 rs17856199) and nitric oxide synthase (NOS2 rs 2297518) genotype combination as potential oxidative stress-related molecular markers for type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2021; 14: 1385-1403.
18.
Chen B, Cao L, Zhou Y, Yang P, Wan HW, Jia GQ, Liu L, Wu XT. Glutathione S-transferase T1 (GSTT1) gene polymorphism and gastric cancer susceptibility: a metaanalysis of epidemiologic studies. Dig Dis Sci 2010; 55: 1831-1838.
19.
Kant Shukla R, Kant S, Mittal B, Bhattacharya S. Comparative study of GST polymorphism in relation to age in COPD and lung cancer. Tuberk Toraks 2013; 61: 275-282.
20.
Song L, Yang C, He XF. Individual and combined effects of GSTM1 and GSTT1 polymorphisms on colorectal cancer risk: an updated meta-analysis. Biosci Rep 2020; 40: BSR20201927.
21.
Nath S, Das S, Bhowmik A, Ghosh SK, Choudhury Y. The GSTM1 and GSTT1 null genotypes increase the risk for type 2 diabetes mellitus and the subsequent development of diabetic complications: a meta-analysis. Curr Diabetes Rev 2019; 15: 31-43.
22.
Higurashi T, Nakajima A. Metformin and colorectal cancer. Front Endocrinol 2018; 9: 622.
23.
Liu F, Yan L, Wang Z, Lu Y, Chu Y, Li X, Liu Y, Rui D, Nie S, Xiang H. Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Oncotarget 2017; 8: 16017-16026.
24.
Liu Y, Jin PP, Sun XC, Hu TT. Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis. Saudi J Gastroenterol 2018; 24: 75-81.
25.
Sun R, Liu JP, Gao C, Xiong YY, Li M, Wang YP, Su YW, Lin M, Jiang AL, Xiong LF, Xie Y, Feng JP. Two variants on T2DM suspectible gene HHEX are associated with CRC risk in a Chinese population. Oncotarget 2015; 7: 29770-29779.
26.
De Kort S, Simons CCJM, van den Brandt PA, JanssenHeijnen MLG, Sanduleanu S, Masclee AAM, Weijenberg MP. Diabetes mellitus, genetic variants in the insulin-like growth factor pathway and colorectal cancer risk. Int J Cancer 2019, 145: 1774-1781.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
